Drug Trial Radar · NCT00413075
Study of Oral PXD101 in Patients With Advanced Solid Tumors or Lymphoma
Last checked: Nov 19, 2026Latest source record: Jul 8, 2015 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
121
Actual
Start
Jun 2006
Primary completion
Aug 2011
Study completion Aug 2011
Sponsor
- Lead sponsor
- Valerio TherapeuticsIndustry
- Sponsor type
- Industry
- Collaborators
- Spectrum Pharmaceuticals, Inc
- First posted
- Dec 19, 2006
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a Phase I dose escalation study of PXD101 administered orally. Oral belinostat will be given once or twice daily at various dosing schedules to patients with solid tumors. Doses will be escalated until the maximum tolerated dose (MTD) is identified. In parallel, a cohort of lymphoma patients will be given oral belinostat on a discontinuous once daily dosing schedule.
Conditions
- Solid Tumor
- Lymphoma
Interventions
oral belinostatDrug
oral belinostat dosed once or twice daily at continuous and discontinuous dosing schedules.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Safety, tolerability and maximum tolerated dose of orally administered PXD101 for each cohortTime frame: throughout the study
Locations
6 sites in 3 countries. Site status is shown where the registry gives one.
Yale New Haven Hospital
New Haven, Connecticut
Columbia University - Herbert Irving Cancer Center
New York, New York
New York University Cancer Institute
New York, New York
M.D. Anderson Cancer Center
Houston, Texas
Research Facility
Copenhagen, Copenhagen, Denmark
Research Facility
London, Surrey, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.